

Listing of Claims

1. (Canceled)

2. (Currently amended) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises:

- a) residues 23-312 of ~~the amino acid sequence set forth as~~ SEQ ID NO: 11;
- b) an amino acid sequence at least 98% identical to ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11; or
- c) an immunogenic fragment comprising at least fifteen consecutive amino acids of ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11, that specifically binds to an antibody that specifically binds ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11,

wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

3. (Currently amended) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises an amino acid sequence at least 98% identical to ~~the amino acid sequence as set forth as~~ residues 23-312 of SEQ ID NO: 11, wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

4. (Currently amended) The *P. ariasi* polypeptide of claim 3, wherein the polypeptide comprises ~~the an~~ an amino acid sequence ~~set forth as~~ at least 99% identical to residues 23-312 of SEQ ID NO: 11.

5. (Currently amended) An immunogenic fragment of the polypeptide of claim 4, wherein the immunogenic fragment comprises at least fifteen consecutive amino acids of ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11, that specifically binds to an antibody that specifically binds ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11.

6 - 24. (Canceled)

25. (Previously presented) An immunogenic composition comprising an effective amount of the polypeptide of claim 2 and a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Withdrawn) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising:

administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

28. (Withdrawn) The method of claim 27, wherein the immune response comprises a T cell response.

29. (Withdrawn) The method of claim 27, wherein the immune response comprises a B cell response.

30. (Withdrawn) The method of claim 27, wherein the subject comprises a non-human veterinary subject.

31. (Withdrawn) The method of claim 27, wherein the subject is a dog.

32. (Withdrawn) The method of claim 27, wherein the subject is a human.

33. (Withdrawn and currently amended) The method of claim 27, wherein the polypeptide comprises ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO:11.

34. (Canceled)

35. (Withdrawn) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a

therapeutically effective amount of the *P. ariasi* polypeptide of claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.

36. (Withdrawn and currently amended) The method of claim 35, wherein the polypeptide comprises ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11.

37 - 79. (Canceled)

80. (Currently amended) The polypeptide of claim 4, wherein the polypeptide ~~consists of~~ comprises an amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.

81. (Previously presented) An immunogenic composition comprising an effective amount of the polypeptide of claim 3 and a pharmaceutically acceptable carrier.

82. (Withdrawn) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising
administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

83. (Withdrawn) The method of claim 82, wherein the immune response comprises a T cell response.

84. (Withdrawn) The method of claim 82, wherein the immune response comprises a B cell response.

85. (Withdrawn) The method of claim 82, wherein the subject comprises a non-human veterinary subject.

86. (Withdrawn) The method of claim 82, wherein the subject is a dog.

87. (Withdrawn) The method of claim 82, wherein the subject is a human.

88. (Withdrawn) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.

89. (Withdrawn and currently amended) The method of claim 88, wherein the polypeptide comprises an amino acid sequence at least 99% identical to ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11.

90. (Withdrawn and currently amended) The method of claim 89, wherein the polypeptide comprises ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11.

91. (Withdrawn and currently amended) The method of claim 90, wherein the polypeptide ~~consists of~~ comprises ~~the amino acid sequence set forth as~~ SEQ ID NO: 11.

92. (Withdrawn and currently amended) The method of claim 82, wherein the polypeptide comprises an amino acid sequence at least 99% identical to ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11.

93. (Withdrawn and currently amended) The method of claim 92, wherein the polypeptide comprises ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11.

94. (Withdrawn and currently amended) The method of claim 93, wherein the polypeptide ~~consists of~~ comprises ~~the amino acid sequence set forth as~~ SEQ ID NO: 11.

95. (Currently amended) The substantially purified salivary *P. ariasi* polypeptide of claim ~~380~~, wherein the polypeptide comprises ~~an amino acid sequence at least 99% identical to~~

~~the amino acid sequence set forth as~~ SEQ ID NO: 11.

96. (Currently amended) The substantially purified salivary *P. ariasi* polypeptide of claim 2, wherein the polypeptide comprises an amino acid sequence at least 99% identical to ~~the amino acid sequence set forth as~~ residues 23-312 of SEQ ID NO: 11.

97. (Currently amended) The substantially purified salivary *P. ariasi* polypeptide of claim 2, wherein the polypeptide comprises ~~the amino acid sequence set forth as~~ SEQ ID NO: 11.

98. (Canceled)